Chairman’s Shareholder Update March 2014 Edwin G. Marshall Chairman of the Board In the Company’s January 23, 2014 press release titled, “Emerging Hospital Disinfection System Should Save Billions”, the critical importance of obtaining complete bactericidal kill in order to break the reinfection cycle in hospitals was discussed. “We have learned that obtaining even a [...]
Edwin G. Marshall
Chairman of the Board
In the Company’s January 23, 2014 press release titled, “Emerging Hospital Disinfection System Should Save Billions”, the critical importance of obtaining complete bactericidal kill in order to break the reinfection cycle in hospitals was discussed. “We have learned that obtaining even a 99.9% bacterial kill is not enough, as the remaining 0.1% of bacteria immediately begin growing back causing the problem of infection to start all over again in a few short hours.” That scientific fact, research proven by Dr Michael Shannon and our team at Innovation Park, was then confirmed in-hospital at Belleville General Hospital (BGH) during the summer of 2013. The demonstrated capability to halt an outbreak of Methicillin-Resistant Staphylococcus aureus (MRSA) that had reached 7 of 14 rooms on one ward with a single AsepticSureâ cleaning was powerful in itself. The hospital’s Chief of Staff, Dr Dick Zoutman, also performed 120 surface cultures across the 7 treated rooms. All 120 cultures came back negative, strongly suggesting 100% kill. Within days it was confirmed the crisis was over following the use of AsepticSure. But there was more to come! The 6-month follow-up confirmed the ward, which had historically averaged one to two new MRSA infections per month had now gone 6 full months without a single new case of MRSA.
THAT WAS THE GAME CHANGER! Our laboratory data was now confirmed in a working hospital. When you truly achieve >6 log (99.9999%) bactericidal kill, a room will remain safe and free of bacteria until another source of bacteria is introduced. AsepticSure has demonstrated a solution to a previously unsolvable problem, by stopping the ongoing reinfection cycle inside a hospital room with a single AsepticSure cleaning.
On February 27th , we then announced the appointment of Mr. David Esposito to Medizone International’s Board of Directors. I have now had the privilege along with Dr Shannon of working with David at business meetings this past week in New York. Having now spent many hours in person and also by telephone in planning and strategy meetings with David, and I speak on behalf of both myself and Dr Shannon, we could not be happier with the synergy we are experiencing in working together. In this regard, I thought shareholders might like to hear directly from David.
Thank you Ed. I see a tremendous opportunity with AsepticSure. The potential to repeat the results we documented at Belleville General Hospital represents a sea-change in hospital infection control strategies and provides a solution to potentially break the reinfection cycle within a hospital. In addition, with the potential to move this technology beyond a hospital setting, this could possibly be one of the largest opportunities to impact patient-health in over a generation. I am excited to become an active member of the team working directly with Dr Shannon, Mr Marshall and everyone involved with this exciting project. I plan on being a very active board member as we focus on increased commercialization. To help accelerate our efforts, I plan to focus my time in the areas of business development and commercial strategy.
The US launch plans are beginning to take shape as we prepare for the anticipated EPA approval of AsepticSure. We are beginning to screen US hospitals with the plan of establishing several demonstration sites to act as early adopters with the intent of replicating similar results that were recently demonstrated at Belleville General Hospital in Ontario. Once we establish a foothold with AsepticSure in several US and Canadian hospitals, and deliver similar results to BGH in breaking the reinfection cycle with AsepticSure, we anticipate the rapid market acceptance of AsepticSure.
In addition to our initial launch plan, I will be working with the rest of the team on initiatives to accelerate penetration with innovative distribution strategies, first within the North American market and then rapidly moving globally.
The AsepticSure system is uniquely positioned to potentially reduce the suffering and death associated with hospital acquired infections (HAI), which still stands as the fourth leading cause of death in the United States and Canada. In addition, as cost pressures within a hospital continue to increase, the AsepticSure system has the potential to greatly reduced hospital operating costs through cost avoidance associated with HAI. With the implementation of the Affordable Care Act in the US and other major initiatives around the world to address escalating hospital-based costs, the opportunity to demonstrate a significant reduction in costs while improving care with the AsepticSure system will be welcomed news to hospital administrators and health-care professionals.
I want to thank the board of directors and shareholders for the opportunity to actively participate in bringing this new reality into health care delivery systems around the world. I believe this is the start of an exciting journey.